Corvus Q4 net loss $6.7M; soquelitinib Orphan Drug; Phase 3 PTCL trial on track

Corvus Pharmaceuticals, Inc.

Net loss $6.7M in Q4 2023 vs $9.8M Q4 2022; cash $27.1M at Dec 31, 2023.
Soquelitinib Phase 1/1b: 7 of 21 evaluable PTCL patients had objective responses (4 CR, 3 PR).
FDA granted Orphan Drug Designation for soquelitinib in T cell lymphoma (Feb 2024).
Registrational Phase 3 PTCL trial expected to initiate Q3 2024; Phase 1 atopic dermatitis trial Q2 2024.
Appointed Jeffrey Arcara as Chief Business Officer to lead corporate strategy and business development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2023 and its financial position as of December 31, 2023, and provided a business update.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.